• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

钙通道阻滞剂使用者患帕金森病风险降低:一项荟萃分析

Reduced Risk of Parkinson's Disease in Users of Calcium Channel Blockers: A Meta-Analysis.

作者信息

Gudala Kapil, Kanukula Raju, Bansal Dipika

机构信息

Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research, SAS Nagar, Punjab 160062, India.

出版信息

Int J Chronic Dis. 2015;2015:697404. doi: 10.1155/2015/697404. Epub 2015 Feb 3.

DOI:10.1155/2015/697404
PMID:26464872
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4590944/
Abstract

Aim. To pool the data currently available to determine the association between calcium channel blockers (CCBs) and risk of Parkinson's disease (PD). Methods. Literature search in PubMed, EBSCO, and Cochrane library was undertaken through March 2014, looking for observational studies evaluating the association between CCBs use and PD. Pooled relative risk (RR) estimates and 95% confidence intervals (CIs) were calculated using random-effects model. Subgroup analyses, sensitivity Analysis, and cumulative meta-analysis were also performed. Results. Six studies were included in our meta-analysis according to the selection criteria, including three cohort studies and three case-control studies involving 27,67,990 subjects including 11,941 PD cases. We found CCBs use was associated with significant decreased risk of PD, compared with not using CCBs (random effects model pooled RR, 0.81 (95% CI, 0.69-0.95)); a significant heterogeneity was found between studies (P = 0.031; I (2) 54.6%). Both the classes of CCB, that is, dihydropyridine calcium channel blockers (DiCCB) (0.80 (95% CI, 0.65-0.98) P = 0.032) and non-DiCCB (0.70 (95% CI, 0.53-0.92) P = 0.013), were found to be reducing the risk of PD. Conclusion. In our analysis, we found that CCBs use was associated with a Significantly decreased risk of PD compared with non-CCB use.

摘要

目的。汇总当前可用数据,以确定钙通道阻滞剂(CCB)与帕金森病(PD)风险之间的关联。方法。截至2014年3月,在PubMed、EBSCO和Cochrane图书馆进行文献检索,寻找评估CCB使用与PD之间关联的观察性研究。使用随机效应模型计算合并相对风险(RR)估计值和95%置信区间(CI)。还进行了亚组分析、敏感性分析和累积荟萃分析。结果。根据选择标准,六项研究纳入我们的荟萃分析,包括三项队列研究和三项病例对照研究,涉及2767990名受试者,其中包括11941例PD病例。我们发现,与未使用CCB相比,使用CCB与PD风险显著降低相关(随机效应模型合并RR,0.81(95%CI,0.69 - 0.95));研究之间存在显著异质性(P = 0.031;I² 54.6%)。发现CCB的两类,即二氢吡啶类钙通道阻滞剂(DiCCB)(0.80(95%CI,0.65 - 0.98)P = 0.032)和非DiCCB(0.70(95%CI,0.53 - 0.92)P = 0.013),均能降低PD风险。结论。在我们的分析中,我们发现与未使用CCB相比,使用CCB与PD风险显著降低相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae23/4590944/305080048712/IJCD2015-697404.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae23/4590944/0dabe8edf267/IJCD2015-697404.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae23/4590944/305080048712/IJCD2015-697404.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae23/4590944/0dabe8edf267/IJCD2015-697404.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae23/4590944/305080048712/IJCD2015-697404.002.jpg

相似文献

1
Reduced Risk of Parkinson's Disease in Users of Calcium Channel Blockers: A Meta-Analysis.钙通道阻滞剂使用者患帕金森病风险降低:一项荟萃分析
Int J Chronic Dis. 2015;2015:697404. doi: 10.1155/2015/697404. Epub 2015 Feb 3.
2
Risk of Parkinson's Disease in the Users of Antihypertensive Agents: An Evidence from the Meta-Analysis of Observational Studies.抗高血压药物使用者患帕金森病的风险:来自观察性研究荟萃分析的证据
J Neurodegener Dis. 2016;2016:5780809. doi: 10.1155/2016/5780809. Epub 2016 Jul 19.
3
Calcium channel blocker use and risk of Parkinson's disease: a meta-analysis.钙通道阻滞剂的使用与帕金森病风险:一项荟萃分析。
Pharmacoepidemiol Drug Saf. 2015 Jun;24(6):559-66. doi: 10.1002/pds.3781. Epub 2015 Apr 2.
4
Calcium channel blockers and Parkinson's disease: a systematic review and meta-analysis.钙通道阻滞剂与帕金森病:一项系统评价和荟萃分析
Ther Adv Neurol Disord. 2024 May 19;17:17562864241252713. doi: 10.1177/17562864241252713. eCollection 2024.
5
Systematic review with meta-analysis: the association between the use of calcium channel blockers and gastrointestinal bleeding.系统评价与荟萃分析:钙通道阻滞剂的使用与胃肠道出血之间的关联
Aliment Pharmacol Ther. 2015 Jun;41(12):1246-55. doi: 10.1111/apt.13211. Epub 2015 Apr 21.
6
Statin use and risk of Parkinson's disease: A meta-analysis.他汀类药物的使用与帕金森病风险:一项荟萃分析。
Behav Brain Res. 2016 Aug 1;309:29-34. doi: 10.1016/j.bbr.2016.04.046. Epub 2016 Apr 27.
7
Association Between the Overall Risk of Prostate Cancer and Use of Calcium Channel Blockers: A Systematic Review and Meta-analysis.钙通道阻滞剂的使用与前列腺癌总体发病风险的相关性:系统评价和荟萃分析。
Clin Ther. 2020 Sep;42(9):1715-1727.e2. doi: 10.1016/j.clinthera.2020.06.021. Epub 2020 Aug 15.
8
Calcium channel blocker use reduces incident dementia risk in elderly hypertensive patients: A meta-analysis of prospective studies.使用钙通道阻滞剂可降低老年高血压患者患痴呆症的风险:一项前瞻性研究的荟萃分析。
Neurosci Lett. 2018 Apr 3;671:120-127. doi: 10.1016/j.neulet.2018.02.027. Epub 2018 Feb 13.
9
Use of calcium channel blockers and Parkinson's disease.钙通道阻滞剂的使用与帕金森病。
Am J Epidemiol. 2012 Apr 1;175(7):627-35. doi: 10.1093/aje/kwr362. Epub 2012 Mar 1.
10
Beta-blockers for hypertension.用于治疗高血压的β受体阻滞剂。
Cochrane Database Syst Rev. 2007 Jan 24(1):CD002003. doi: 10.1002/14651858.CD002003.pub2.

引用本文的文献

1
Update: Protective and risk factors for Parkinson disease.更新:帕金森病的保护和风险因素。
Parkinsonism Relat Disord. 2024 Aug;125:107026. doi: 10.1016/j.parkreldis.2024.107026. Epub 2024 Jun 13.
2
Parkinson's Disease: Cells Succumbing to Lifelong Dopamine-Related Oxidative Stress and Other Bioenergetic Challenges.帕金森病:细胞长期遭受多巴胺相关氧化应激和其他生物能量挑战的影响。
Int J Mol Sci. 2024 Feb 7;25(4):2009. doi: 10.3390/ijms25042009.
3
Naphthoquinones as a Promising Class of Compounds for Facing the Challenge of Parkinson's Disease.

本文引用的文献

1
Parkinson's disease: a review.帕金森病:综述
Front Biosci (Schol Ed). 2014 Jan 1;6(1):65-74. doi: 10.2741/s415.
2
Altered resting state brain networks in Parkinson's disease.帕金森病患者的静息态脑网络改变。
PLoS One. 2013 Oct 28;8(10):e77336. doi: 10.1371/journal.pone.0077336. eCollection 2013.
3
Parkinson's disease is associated with altered expression of CaV1 channels and calcium-binding proteins.帕金森病与 CaV1 通道和钙结合蛋白的表达改变有关。
萘醌类化合物是应对帕金森病挑战的一类有前景的化合物。
Pharmaceuticals (Basel). 2023 Nov 8;16(11):1577. doi: 10.3390/ph16111577.
4
Feed-forward metabotropic signaling by Cav1 Ca channels supports pacemaking in pedunculopontine cholinergic neurons.Cav1 钙通道的前馈代谢型信号支持脑桥被盖核胆碱能神经元的起搏。
Neurobiol Dis. 2023 Nov;188:106328. doi: 10.1016/j.nbd.2023.106328. Epub 2023 Oct 16.
5
Upregulated DNA Damage-Linked Biomarkers in Parkinson's Disease Model Mice.帕金森病模型小鼠中上调的与 DNA 损伤相关的生物标志物。
ASN Neuro. 2023 Jan-Dec;15:17590914231152099. doi: 10.1177/17590914231152099.
6
Ca channels couple spiking to mitochondrial metabolism in substantia nigra dopaminergic neurons.钙通道将黑质多巴胺能神经元的动作电位发放与线粒体代谢相偶联。
Sci Adv. 2022 Sep 30;8(39):eabp8701. doi: 10.1126/sciadv.abp8701.
7
The Role of Voltage-Gated Calcium Channels in Basal Ganglia Neurodegenerative Disorders.电压门控钙通道在基底神经节神经退行性疾病中的作用。
Curr Neuropharmacol. 2023;21(2):183-201. doi: 10.2174/1570159X20666220327211156.
8
Shared Molecular Targets in Parkinson's Disease and Arterial Hypertension: A Systematic Review.帕金森病与动脉高血压的共同分子靶点:一项系统综述
Biomedicines. 2022 Mar 11;10(3):653. doi: 10.3390/biomedicines10030653.
9
Post-Translational Modification of Cav1.2 and its Role in Neurodegenerative Diseases.Cav1.2的翻译后修饰及其在神经退行性疾病中的作用
Front Pharmacol. 2022 Jan 17;12:775087. doi: 10.3389/fphar.2021.775087. eCollection 2021.
10
Drug repurposing strategies of relevance for Parkinson's disease.与帕金森病相关的药物再利用策略。
Pharmacol Res Perspect. 2021 Aug;9(4):e00841. doi: 10.1002/prp2.841.
Brain. 2013 Jul;136(Pt 7):2077-97. doi: 10.1093/brain/awt134. Epub 2013 Jun 14.
4
CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease. Cav1.3 选择性 L 型钙通道拮抗剂有望成为帕金森病的新型治疗药物。
Nat Commun. 2012;3:1146. doi: 10.1038/ncomms2149.
5
Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson's disease and other synucleinopathies.针对细胞内和细胞外的α-突触核蛋白作为帕金森病和其他突触核蛋白病的治疗策略。
Expert Opin Ther Targets. 2012 Apr;16(4):421-32. doi: 10.1517/14728222.2012.674111.
6
Use of calcium channel blockers and Parkinson's disease.钙通道阻滞剂的使用与帕金森病。
Am J Epidemiol. 2012 Apr 1;175(7):627-35. doi: 10.1093/aje/kwr362. Epub 2012 Mar 1.
7
Anti-hypertensive drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies and clinical trials.抗高血压药物作为帕金森病的疾病修饰药物:来自观察性研究和临床试验的证据。
Cochrane Database Syst Rev. 2011 Nov 9(11):CD008535. doi: 10.1002/14651858.CD008535.pub2.
8
Association of blood pressure and hypertension with the risk of Parkinson disease: the National FINRISK Study.血压和高血压与帕金森病风险的关联:芬兰国家 FINRISK 研究。
Hypertension. 2011 Jun;57(6):1094-100. doi: 10.1161/HYPERTENSIONAHA.111.171249. Epub 2011 May 2.
9
Calcium channel blocker use and risk of Parkinson's disease.钙通道阻滞剂的使用与帕金森病风险。
Mov Disord. 2010 Sep 15;25(12):1818-22. doi: 10.1002/mds.23191.
10
L-type calcium channel blockers and Parkinson disease in Denmark.L 型钙通道阻滞剂与丹麦的帕金森病。
Ann Neurol. 2010 May;67(5):600-6. doi: 10.1002/ana.21937.